skip to Main Content

Qualisure Diagnostics Inc. develops molecular tests that enhance cancer care by identifying features that help oncologists to personalize treatments. Each of our biomarkers is designed to influence clinical decision-making and to facilitate Precision Medicine.

Understanding which cancers are indolent or aggressive, and which ones are more likely to respond to certain treatments can guide an oncologist to recommend a treatment strategy that is optimized for each patient. Our precision diagnostics – discovered using our own machine learning algorithms – minimize the burden of cancer treatment by avoiding toxic and costly treatments that are unlikely to provide benefit.

Guiding cancer care better.

Appropriateness of care. It’s what we are all striving for. Appropriateness of care includes giving the right treatment to the right person at the right time. It’s good for patients, good for doctors, good for insurers.

Oncologists use their experience and judgement to select the best treatments for their patients. But sometimes those treatments can be toxic and seriously affect their patients’ quality of life. And, they can be costly.

What if there was a better way?

By developing tools for Precision Medicine, we can identify the right person for the right treatment. Qualisure Diagnostics is dedicated to creating those tools. Using cutting edge machine-learning approaches, we decode the tumor’s genome, identifying the unique molecular signatures that predict how a person’s cancer will behave. We use those signatures to engineer our clinical tests. And our clinical tests have the capability to guide important clinical decisions, helping health care teams decide on the best, most appropriate treatment that will ultimately have the best outcome with the least toxic effects.